ARDX Ardelyx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARDX

Price (delayed)

$8.94

Market cap

$2.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.29

Enterprise value

$2.16B

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate ...

Highlights
The company's revenue has surged by 152% YoY and by 28% QoQ
The company's gross profit has surged by 136% YoY and by 27% QoQ
Ardelyx's equity has increased by 20% YoY but it has decreased by 10% QoQ
Ardelyx's debt has surged by 194% YoY and by 87% QoQ
The company's gross margin fell by 6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ardelyx.com
Peers: OPK AMGN ABT AZN

Key stats

What are the main financial stats of ARDX
Market
Shares outstanding
233.98M
Market cap
$2.09B
Enterprise value
$2.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.79
Price to sales (P/S)
13.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.58
Earnings
Revenue
$159.11M
EBIT
-$58.88M
EBITDA
-$53.48M
Free cash flow
-$81.12M
Per share
EPS
-$0.29
Free cash flow per share
-$0.35
Book value per share
$0.65
Revenue per share
$0.68
TBVPS
$1.47
Balance sheet
Total assets
$342.38M
Total liabilities
$191.49M
Debt
$104.93M
Equity
$150.89M
Working capital
$201.04M
Liquidity
Debt to equity
0.7
Current ratio
4.53
Quick ratio
4.06
Net debt/EBITDA
-1.29
Margins
EBITDA margin
-33.6%
Gross margin
85.3%
Net margin
-41.4%
Operating margin
-38.9%
Efficiency
Return on assets
-23.1%
Return on equity
-41.7%
Return on invested capital
-22.7%
Return on capital employed
-20.6%
Return on sales
-37%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARDX stock price

How has the Ardelyx stock price performed over time
Intraday
-3.97%
1 week
35.25%
1 month
22.13%
1 year
113.37%
YTD
44.19%
QTD
22.47%

Financial performance

How have Ardelyx's revenue and profit performed over time
Revenue
$159.11M
Gross profit
$135.72M
Operating income
-$61.89M
Net income
-$65.81M
Gross margin
85.3%
Net margin
-41.4%
The company's revenue has surged by 152% YoY and by 28% QoQ
The company's gross profit has surged by 136% YoY and by 27% QoQ
ARDX's operating margin has surged by 60% year-on-year and by 23% since the previous quarter
Ardelyx's net margin has surged by 60% YoY and by 22% QoQ

Growth

What is Ardelyx's growth rate over time

Valuation

What is Ardelyx stock price valuation
P/E
N/A
P/B
13.79
P/S
13.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.58
The EPS has increased by 17% year-on-year and by 3.3% since the previous quarter
ARDX's P/B is 89% above its last 4 quarters average of 7.6
Ardelyx's equity has increased by 20% YoY but it has decreased by 10% QoQ
The company's revenue has surged by 152% YoY and by 28% QoQ
The price to sales (P/S) is 80% lower than the 5-year quarterly average of 67.8 but 47% higher than the last 4 quarters average of 9.3

Efficiency

How efficient is Ardelyx business performance
The company's return on invested capital has surged by 73% YoY and by 27% QoQ
The return on sales has surged by 62% year-on-year and by 24% since the previous quarter
Ardelyx's ROE has increased by 46% YoY and by 4.4% from the previous quarter
Ardelyx's ROA has increased by 40% YoY and by 11% from the previous quarter

Dividends

What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARDX.

Financial health

How did Ardelyx financials performed over time
ARDX's total assets is 79% greater than its total liabilities
ARDX's total liabilities has surged by 109% year-on-year and by 46% since the previous quarter
The company's quick ratio has surged by 80% YoY
Ardelyx's debt is 30% lower than its equity
Ardelyx's debt has surged by 194% YoY and by 87% QoQ
Ardelyx's debt to equity has surged by 150% YoY and by 106% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.